Literature DB >> 23881914

DEPTOR regulates vascular endothelial cell activation and proinflammatory and angiogenic responses.

Sarah Bruneau1, Hironao Nakayama, Craig B Woda, Evelyn A Flynn, David M Briscoe.   

Abstract

The maintenance of normal tissue homeostasis and the prevention of chronic inflammatory disease are dependent on the active process of inflammation resolution. In endothelial cells (ECs), proinflammation results from the activation of intracellular signaling responses and/or the inhibition of endogenous regulatory/pro-resolution signaling networks that, to date, are poorly defined. In this study, we find that DEP domain containing mTOR interacting protein (DEPTOR) is expressed in different microvascular ECs in vitro and in vivo, and using a small interfering RNA (siRNA) knockdown approach, we find that it regulates mammalian target of rapamycin complex 1 (mTORC1), extracellular signal-regulated kinase 1/2, and signal transducer and activator of transcription 1 activation in part through independent mechanisms. Moreover, using limited gene arrays, we observed that DEPTOR regulates EC activation including mRNA expression of the T-cell chemoattractant chemokines CXCL9, CXCL10, CXCL11, CX3CL1, CCL5, and CCL20 and the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 (P < .05). DEPTOR siRNA-transfected ECs also bound increased numbers of peripheral blood mononuclear cells (P < .005) and CD3+ T cells (P < .005) in adhesion assays in vitro and had increased migration and angiogenic responses in spheroid sprouting (P < .01) and wound healing (P < .01) assays. Collectively, these findings define DEPTOR as a critical upstream regulator of EC activation responses and suggest that it plays an important role in endogenous mechanisms of anti-inflammation and pro-resolution.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23881914      PMCID: PMC3765062          DOI: 10.1182/blood-2013-03-488486

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  49 in total

1.  Functional characterization of glycine N-methyltransferase and its interactive protein DEPDC6/DEPTOR in hepatocellular carcinoma.

Authors:  Chia-Hung Yen; Yao-Cheng Lu; Chung-Hsien Li; Cheng-Ming Lee; Chia-Yen Chen; Ming-Yuan Cheng; Shiu-Feng Huang; Kuen-Feng Chen; Ann-Lii Cheng; Li-Ying Liao; Yan-Hwa Wu Lee; Yi-Ming Arthur Chen
Journal:  Mol Med       Date:  2012-03-30       Impact factor: 6.354

2.  Effect of vascular endothelial growth factor and its receptor KDR on the transendothelial migration and local trafficking of human T cells in vitro and in vivo.

Authors:  Monika Edelbauer; Dipak Datta; Ingrid H C Vos; Aninda Basu; Maria P Stack; Marlies E J Reinders; Masayuki Sho; Katiana Calzadilla; Peter Ganz; David M Briscoe
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

3.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor.

Authors:  Markus Guba; Philipp von Breitenbuch; Markus Steinbauer; Gudrun Koehl; Stefanie Flegel; Matthias Hornung; Christiane J Bruns; Carl Zuelke; Stefan Farkas; Matthias Anthuber; Karl-Walter Jauch; Edward K Geissler
Journal:  Nat Med       Date:  2002-02       Impact factor: 53.440

4.  Overexpression of DEP domain containing mTOR-interacting protein correlates with poor prognosis in differentiated thyroid carcinoma.

Authors:  Lei Pei; Pingfang Xie; Enxiang Zhou; Qian Yang; Yi Luo; Zhonghua Tang
Journal:  Mol Med Rep       Date:  2011-06-02       Impact factor: 2.952

5.  Negative regulation of the serine/threonine kinase B-Raf by Akt.

Authors:  K L Guan; C Figueroa; T R Brtva; T Zhu; J Taylor; T D Barber; A B Vojtek
Journal:  J Biol Chem       Date:  2000-09-01       Impact factor: 5.157

6.  TRAF6 inhibits proangiogenic signals in endothelial cells and regulates the expression of vascular endothelial growth factor.

Authors:  Sarah Bruneau; Dipak Datta; Jesse A Flaxenburg; Soumitro Pal; David M Briscoe
Journal:  Biochem Biophys Res Commun       Date:  2012-02-02       Impact factor: 3.575

7.  Dynamic balancing: DEPTOR tips the scales.

Authors:  Christopher G Proud
Journal:  J Mol Cell Biol       Date:  2009-08-25       Impact factor: 6.216

Review 8.  Targeting the intragraft microenvironment and the development of chronic allograft rejection.

Authors:  Olivier Dormond; Marc Dufour; Tatsuichiro Seto; Sarah Bruneau; David M Briscoe
Journal:  Hum Immunol       Date:  2012-08-03       Impact factor: 2.850

9.  An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1.

Authors:  Carson C Thoreen; Seong A Kang; Jae Won Chang; Qingsong Liu; Jianming Zhang; Yi Gao; Laurie J Reichling; Taebo Sim; David M Sabatini; Nathanael S Gray
Journal:  J Biol Chem       Date:  2009-01-15       Impact factor: 5.157

10.  Pro-Resolving Lipid Mediators (SPMs) and Their Actions in Regulating miRNA in Novel Resolution Circuits in Inflammation.

Authors:  Antonio Recchiuti; Charles N Serhan
Journal:  Front Immunol       Date:  2012-10-22       Impact factor: 7.561

View more
  20 in total

Review 1.  Translational implications of endothelial cell dysfunction in association with chronic allograft rejection.

Authors:  Sarah Bruneau; Johannes Wedel; Fadi Fakhouri; Hironao Nakayama; Leo Boneschansker; Daniel Irimia; Kevin P Daly; David M Briscoe
Journal:  Pediatr Nephrol       Date:  2015-04-24       Impact factor: 3.714

Review 2.  Chronic allograft rejection: a fresh look.

Authors:  Johannes Wedel; Sarah Bruneau; Nora Kochupurakkal; Leo Boneschansker; David M Briscoe
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

3.  Antibodies to HLA Molecules Mimic Agonistic Stimulation to Trigger Vascular Cell Changes and Induce Allograft Injury.

Authors:  Nicole M Valenzuela; Elaine F Reed
Journal:  Curr Transplant Rep       Date:  2015-05-24

4.  DEPTOR is a direct NOTCH1 target that promotes cell proliferation and survival in T-cell leukemia.

Authors:  Y Hu; H Su; C Liu; Z Wang; L Huang; Q Wang; S Liu; S Chen; J Zhou; P Li; Z Chen; H Liu; G Qing
Journal:  Oncogene       Date:  2016-09-05       Impact factor: 9.867

5.  Outside-in HLA class I signaling regulates ICAM-1 clustering and endothelial cell-monocyte interactions via mTOR in transplant antibody-mediated rejection.

Authors:  Sahar Salehi; Rebecca A Sosa; Yi-Ping Jin; Shoichi Kageyama; Michael C Fishbein; Enrique Rozengurt; Jerzy W Kupiec-Weglinski; Elaine F Reed
Journal:  Am J Transplant       Date:  2017-11-23       Impact factor: 8.086

6.  WNT pathway signaling is associated with microvascular injury and predicts kidney transplant failure.

Authors:  Michael E Seifert; Joseph P Gaut; Boyi Guo; Sanjay Jain; Andrew F Malone; Feargal Geraghty; Deborah L Della Manna; Eddy S Yang; Nengjun Yi; Daniel C Brennan; Roslyn B Mannon
Journal:  Am J Transplant       Date:  2019-05-10       Impact factor: 8.086

7.  Rtp801 suppression of epithelial mTORC1 augments endotoxin-induced lung inflammation.

Authors:  Aaron M Nadon; Mario J Perez; Daniel Hernandez-Saavedra; Lynelle P Smith; Yimu Yang; Linda A Sanders; Aneta Gandjeva; Jacob Chabon; Daniel E Koyanagi; Brian B Graham; Rubin M Tuder; Eric P Schmidt
Journal:  Am J Pathol       Date:  2014-07-09       Impact factor: 4.307

8.  Regulation of mTOR Signaling by Semaphorin 3F-Neuropilin 2 Interactions In Vitro and In Vivo.

Authors:  Hironao Nakayama; Sarah Bruneau; Nora Kochupurakkal; Silvia Coma; David M Briscoe; Michael Klagsbrun
Journal:  Sci Rep       Date:  2015-07-09       Impact factor: 4.379

Review 9.  Deptor: not only a mTOR inhibitor.

Authors:  Valeria Catena; Maurizio Fanciulli
Journal:  J Exp Clin Cancer Res       Date:  2017-01-13

10.  High DEPTOR expression correlates with poor prognosis in patients with esophageal squamous cell carcinoma.

Authors:  Nan-Bo Liu; Jun-Hua Zhang; Yu-Fan Liu; Jun Li; Zhen-Zhong Zhang; Ji-Wei Li; Wen-Yue Liu; Chen Huang; Tao Shen; Cheng-Wei Gu; Dong-Yun Gao; Xia Wu; Xu Wu
Journal:  Onco Targets Ther       Date:  2015-11-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.